OSPOMYV AND XBRYK Q Code: Q5159

Drug & Product Overview

HCPCS Descriptor Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg

HCPCS Added Date October 1, 2025

Manufacturer Cordavis

Route of Administration Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About OSPOMYV AND XBRYK

Ospomyv AND Xbryk is a medication aligned to the HCPCS Q Code: Q5159 for billing, pricing, and reimbursement purposes in the United States. This Osteoporosis medication is administered via the subcutaneous route and manufactured by Cordavis.

Manufacturers, reach out to us to add more information.

NDC Code Information

1 NDC package is crosswalked to Q5159. Package detail is available to logged-in subscribers.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
•••••-••••-•• Log in to view	OSPOMYV AND XBRYK

Login to view 1 NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

OSPOMYV AND XBRYK Pricing & Reimbursement

Q5159 Private Payer Reimbursement

$16.27 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Denosumab Biosimilar Information:

OSPOMYV AND XBRYK Approval Date: February 13, 2025

Product Name	HCPCS Code	Active Ingredient	BLA Type
Prolia	J0897	Denosumab	351(a) Originator Product
Jubbonti and Wyost	Q5136	Denosumab	351(k) Interchangeable
Stoboclo and Osenvelt	Q5157	Denosumab	351(k) Interchangeable
Bomyntra and Conexxence	Q5158	Denosumab	351(k) Interchangeable
Ospomyv and Xbryk	Q5159	Denosumab	351(k) Interchangeable
Aukelso and Bosaya	Q5161	Denosumab	351(k) Interchangeable
Bildyos and Bilprevda	Q5162	Denosumab	351(k) Interchangeable
Oziltus	Q5165	Denosumab	351(k) Interchangeable
Osvyrti and Jubereq	Q5166	Denosumab	351(k) Interchangeable
Enoby and Xtrenbo	Q5167	Denosumab	351(k) Interchangeable
Boncresa	Q5171	Denosumab	351(k) Interchangeable
Ponlimsi	Q5173	Denosumab	351(k) Interchangeable

OSPOMYV AND XBRYK CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

OSPOMYV AND XBRYK Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Bone loss in men receiving androgen deprivation therapy for prostate cancer Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer Glucocorticoid-induced osteoporosis Men with osteoporosis at high risk for fracture Postmenopausal women with osteoporosis at high risk for fracture

Drug Class

RANK Ligand Blocking Activity [MoA]RANK Ligand Inhibitor [EPC]

Frequently Asked Questions

Is there an available Ospomyv And Xbryk billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for Ospomyv And Xbryk.

Are there any available Ospomyv And Xbryk patient assistance programs?

Our team has not identified a manufacturer-published source of patient assitance information for Ospomyv And Xbryk.

Where can I find Ospomyv and Xbryk prescribing information?

Ospomyv And Xbryk prescribing information can be found through the link below. Visit Here →

Where can I find Ospomyv And Xbryk side effect information?

Ospomyv And Xbryk side effect information can be found at the link below. Visit Here →

Does billing Ospomyv And Xbryk require wastage modifiers?

CMS does not include OSPOMYV AND XBRYK (Q5159) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5159. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.